...
【24h】

Thiazide-Induced Dysglycemia

机译:噻嗪类引起的血糖异常

获取原文

摘要

There are >70-million hypertensive individuals in the United States, and >45-million persons take antihypertensive medications.1,2 Despite the results of the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT), other trials, and the recommendations in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, well under 50% of these regimens include a thiazide-type diuretic.2,3 In the Department of Veterans’ Affairs, which participated in several of the studies supporting the use of thiazide diuretics, ≈35% of hypertensive patients on pharmacotherapy had a thiazide diuretic included in their hypertension treatment regimens in 2003.4 In private patient encounters, thiazide diuretic use rose from 19% of all of the antihypertensive patient visits in 2002 to 26% in 2004.5The recommendations for preferred use of thiazide-type diuretics are based on >4 decades of clinical trials, including active-controlled trials, where diuretics were tested against other drugs for their efficacy in preventing hard clinical outcomes, such as myocardial infarction, death, stroke, heart failure, and renal failure. ALLHAT, a randomized, double-blind, active-controlled antihypertensive treatment trial in 42 418 patients assigned to a thiazide-type diuretic, an angiotensin-converting enzyme (ACE) inhibitor, a calcium channel-blocker, (average follow-up: 4.9 years), or the doxazosin/chlorthalidone comparison (terminated early, average follow-up: 3.2 years) showed that the diuretic was at least as beneficial as the comparator drugs in lowering blood pressure (BP) and preventing cardiovascular (CV) and renal outcomes and was superior for preventing heart failure (versus each comparator arm), combined CV events (versus α-blocker and ACE-inhibitor arms), and stroke (versus ACE inhibitor [black subjects only] and α-blocker).6 The ongoing success of thiazide-type diuretics in large, adequately powered hypertension outcome trials and new guidelines have created the basis for increased diuretic use.2,6However, clinical trials have also frequently shown potentially …
机译:在美国,有超过7,000万人患有高血压,并且有超过4,500万人服用抗高血压药物。1,2尽管进行了抗高血压和降脂治疗以预防心脏病发作试验(ALLHAT),其他试验和根据全国预防,检测,评估和治疗高血压联合委员会第七次报告中的建议,这些方案中不到50%包括噻嗪类利尿剂。2,3在退伍军人事务部,该研究参加了一些支持使用噻嗪类利尿剂的研究,2003年,约有35%接受药物治疗的高血压患者在其高血压治疗方案中使用了噻嗪类利尿剂。4在私人患者中,使用噻嗪类利尿剂的比例从19%上升到2002年所有降压患者访视率在2004.5中达到26%,首选使用噻嗪类利尿剂的建议是基于> 4年的临床试验,包括•一项主动对照试验,其中利尿药与其他药物进行了对照,以检验它们在预防硬性临床结局(例如心肌梗塞,死亡,中风,心力衰竭和肾衰竭)中的功效。 ALLHAT是一项针对42418例患者的随机,双盲,主动控制性降压治疗试验,分配给噻嗪类利尿剂,血管紧张素转换酶(ACE)抑制剂,钙通道阻滞剂,(平均随访:4.9年或多沙唑嗪/氯噻酮比较(终止,早期平均随访:3.2年)显示,利尿剂在降低血压(BP)和预防心血管(CV)和肾结局方面至少与对照药物一样有益并且在预防心力衰竭(相对于每个比较器组),合并CV事件(相对于α受体阻滞剂和ACE抑制剂组)和中风(相对于ACE抑制剂(仅适用于黑色受试者)和α阻滞剂)方面具有优势。6持续的成功大型,有足够动力的高血压结果试验中噻嗪类利尿剂的使用和新指南为增加利尿剂的使用奠定了基础。2,6然而,临床试验也经常显示出潜在的…

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号